Chemoprevention of melanoma

Current Oncology Reports

Volumn 6, Issue 5, 2004, Pages 406-413

  Demierre, Marie France ^a   Merlino, Glenn ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATORVASTATIN; BIOLOGICAL MARKER; CAROTENOID; CURCUMIN; CYCLIN DEPENDENT KINASE; CYCLOOXYGENASE 2 INHIBITOR; EPIGALLOCATECHIN GALLATE; FARNESYL DIPHOSPHATE; FLAVONOID; GAMMA INTERFERON; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELANOCORTIN 1 RECEPTOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; RESVERATROL; RETINOID; RHO FACTOR; SIMVASTATIN; UNINDEXED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CONTROL; CANCER INCIDENCE; CANCER RESEARCH; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; FIBRINOLYSIS; GENE MUTATION; GENETIC ENGINEERING; GENOMICS; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; MELANOMA; MOLECULAR MECHANICS; MOUSE; MUSCLE DISEASE; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; POINT MUTATION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SKIN IRRITATION; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UNITED STATES;

EID: 4544336843     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0068-4     Document Type: Review

References (78)

1. Geller AC, Miller DR, Annas GD, et al.: Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002, 288:1719-1720.
2. Demierre MF: Time for the national legislation of indoor tanning to protect minors. Arch Dermatol 2003, 139:520-524.
3. Edwards BK, Howe HL, Ries LA, et al.: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766-2792.
4. Demierre MF, Nathanson L: Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003, 21:158-165.
5. Sporn MB, Dunlop NM, Newton DL, et al.: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332-1338.
6. Lippman SM, Hong WK: Cancer prevention by delay. Clin Cancer Res 2002, 8:305-313.
7. Greenwald P: Science, medicine, and the future: cancer chemoprevention. BMJ 2002, 324:714-718.
8. Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003, 3:559-570.
9. Jhappan C, Noonan FP, Merlino G: Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003, 22:3099-3112.
10. Merlino G, Noonan FP: Modeling gene-environment interactions in malignant melanoma. Trends Mol Med 2003, 9:102-108.
11. Noonan FP, Recio JA, Takayama H, et al.: Neonatal sunburn and melanoma in mice. Nature 2001, 413:271-272.
12. Kannan K, Sharpless NE, Xu J, et al.: Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 2003, 100:1221-1225.
13. Demunter A, Stas M, Degreef H, et al.: Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001, 117:1483-1489.
14. Omholt K, Karsberg S, Platz A, et al.: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8:3468-3474.
15. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
16. Busca R, Abbe P, Mantoux F, et al.: Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000, 19:2900-2910.
17. Brose MS, Volpe P, Feldman M, et al.: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
18. Pollock PM, Harper UL, Hansen KS, et al.: High frequency of BRAF mutations in nevi. Nat Genet 2003, 33:19-20.
19. Reifenberger J, Knobbe CB, Sterzinger AA, et al.: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004, 109:377-384.
20. Bishop DT, Demenais F, Goldstein AM, et al.: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94:894-903.
21. Box NF, Duffy DL, Chen W, et al.: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001, 69:765-773.
22. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
23. Hussein MR, Haemel AK, Wood GS: Apoptosis and melanoma: molecular mechanisms. J Pathol 2003, 199:275-288.
24. Ivanov VN, Bhoumik A, Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161.
25. Grossman D, Altieri DC: Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 201:3-11.
26. Grossman D, Kim PJ, Schechner JS, et al.: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001, 98:635-640.
27. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42-49.
28. Serrone L, Hersey P: The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999, 9:51-58.
29. Satyamoorthy K, Bogenrieder T, Herlyn M: No longer a molecular black box: new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 2001, 7:191-194.
30. Hersey P, Zhang XD: How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001, 1:142-150.
31. Dhawan P, Singh AB, Ellis DL, et al.: Constitutive activation of Akt/protein Kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002, 15:7335-7342.
32. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 2003, 22:3113-3122.
33. Stahl JM, Cheung M, Sharma A, et al.: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003, 63:2881-2890.
34. Pennati M, Colella G, Folini M, et al.: Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002, 109:285-286.
35. Soengas MS, Capodieci P, Polsky D, et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
36. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003, 104:527-532.
37. Smalley KS, Eisen TG: Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 2002, 12:187-192.
38. Satyamoorthy K, Li G, Gerrero MR, et al.: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759.
39. Govindarajan B, Bai X, Cohen C, et al.: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003, 278:9790-9795.
40. Urquhart JL, Meech SJ, Marr DG, et al.: Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 2002, 119:556-561.
41. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
42. Fenton RG, Hixon JA, Wright PW, et al.: Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res 1998, 8:3391-3400.
43. Chin L, Tam A, Pomerantz J, et al.: Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
44. Papp T, Pemsel H, Zimmermann R, et al.: Mutational analysis of the N-ras, p53, p161NK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999, 36:610-614.
45. Gorden A, Osman I, Gai W, et al.: Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003, 63:3955-3957.
46. Dong J, Phelps RG, Qiao RF, et al.: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63:3883-3885.
47. Tsao H, Goel V, Wu H, et al.: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122:337-341.
48. Cruz III F, Rubin BP, Wilson D, et al.: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003, 63:5761-5766.
49. Rimoldi D, Salvi S, Lienard D, et al.: Lack of BRAF mutations in uveal melanoma. Cancer Res 2003, 63:2412-5715.
50. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074.
51. Flaherty KT, Lee RJ, Humphries PJ, et al.: Phase I trial of BAY 43-9006 in combination with carboplatin and paclitaxel. Proc ASCO 2003, 22:710 (abstract 2854).
52. Clark EA, Golub TR, Lander ES, et al.: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000, 406:532-535.
53. Colisson EA, Carranza DC, Chen IY et al.: Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol 2002, 119:1172-1176.
54. Graaf MR, Beiderbeck AB, Egberts ACG, et al.: The risk of cancer in users of statins [abstract]. Proc ASCO 2003, 22:846.
55. Dellavalle RP, Nicholas MK, Schilling LM: Melanoma chemo-prevention: a role for statins or fibrates? Am J Ther 2003, 10:203-210.
56. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
57. Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003, 95:844-846.
58. Agarwal B, Halmos B, Feoktistov A, et al.: Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002, 23:521-528.
59. Collisson EA, Kleer C, Wei M, et al.: Atorvastatin prevents RhoC isoprenylation, invasion and metastasis in human melanoma cells. Mol Cancer Ther 2003, 2:941-948.
60. Essig M, Nguyen G, Prie D, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683-690.
61. Ornstein DL, Zacharski LR: Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001, 73:157-161.
62. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
63. Heart Protection Study Collaborative G: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
64. Lluria-Prevatt M, Morreale J, Gregus J, et al.: Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 2002, 11:573-579.
65. Powell BM, Alberts DS, Lluria-Prevatt M: Preclinical and clinical activity of Apomine, a novel biophosphonate ester, in the prevention and treatment of melanoma [abstract]. Proc Am Assoc Cancer Res 2002, 43:1007.
66. F'Guyer S, Afaq F, Mukhtar H: Photochemoprevention of skin cancer by botanical agents. Photodermatol Photoimmunol Photomed 2003, 19:56-72.
67. Afaq F, Ahmad N, Mukhtar H: Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice. Oncogene 2003, 22:9254-9264.
68. Duff M, Stapleton PP, Mestre JR, et al.: Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann Surg Oncol 2003, 10:305-313.
69. Vogt T, McClelland M, Jung B, et al.: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001, 11:587-599.
70. Zhang C, Hazarika P, Ni X, et al.: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002, 8:1234-1240.
71. Tucker MA, Halpern A, Holly EA, et al.: Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997, 277:1439-1444.
72. Goggins WB, Tsac, H: A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003, 97:639-643.
73. Arumi-Uria M, McNutt NS, Finnerty B: Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003, 16:764-771.
74. Marghoob AA, Kopf AW, Rigel DS, et al.: Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome: a case-control study. Arch Dermatol 1994, 130:993-998.
75. Greene M, Clark WH Jr, Tucker MA, et al.: High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102:458-465.
76. Buckmeier JA, Einspahr J, Hart NK, et al.: Differential expression of VEGF, CD31, CD105, and p53 in benign nevi, dysplastic nevi and primary melanoma [abstract]. Proc Am Assoc Cancer Res Front Cancer Prev 2003, 2:119.
77. Ewanowich C, Brynes RK, Medeiros L, et al.: Cyclin D1 expression in clysplastic nevi: an immunohistochemical study. Arch Pathol Lab Med 2001, 125:208-210.
78. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al.: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002, 8:314-346.